Inhalation Sciences Sweden AB
Edit

Inhalation Sciences Sweden AB

http://www.inhalation.se/
Last activity: 13.01.2025
Active
Categories: BioTechDrugEquipmentITLifeMedTechProductResearchScienceTools
We believe in excellence, and we measure it by results. Our clients know that our dry powder aerosol generating platform, PreciseInhale, delivers regional lung data of a quality far beyond other inhalation technologies. PreciseInhale lets them carry out a full PK study using just 50-100 mg of test substance delvering results with a typical standard deviation of <10%.SD. Our in vitro capabilities are widely recognized as world-leading, bringing clients closer than ever to full IVIVC.

PreciseInhale can include a series of exposure modules (from in vitro through to in vivo to clinical.) It can generate respirable dry powder aerosols from preclinical cell studies all the way through to human clinical trials, providing a translational ladder for inhalation R&D programs.

Visit our website:
http://www.inhalation.se/

Visit our labs:
We welcome visitors to our labs in Stockholm, Sweden

Kliniskt Forskningscentrum KFC
Novum plan 6 hiss A
Hälsovägen 7
141 57 Huddinge, Sweden

Visitor entrance, Blickagången 6, elevator E, level 6
Likes
310
Mentions
110
Location: Sweden, Huddinge
Employees: 11-50
Total raised: $1.42M
Founded date: 2005

Investors 2

Funding Rounds 13

DateSeriesAmountInvestors
10.01.2025-$19.02K-
17.12.2024-$35.56K-
13.06.2024-$61.62K-
21.05.2024-$65.19K-
29.12.2023-$52K-
08.11.2023-$58.36K-
16.10.2023-$199.24K-
25.05.2023-$134.04K-
21.03.2023-$126.29K-
31.01.2023-$87.34K-
Show more

Mentions in press and media 110

DateTitleDescription
13.01.2025Inhalation Sciences’ launch of the XposeALI[®] in vitro module with microperfusionInhalation Sciences’ launch of the XposeALI[®] in vitro module with microperfusion Mon, Jan 13, 2025 08:30 CET Report this content (Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s X...
10.01.2025Inhalation Sciences: Pioneering the Future of Inhalation TherapyInhalation Sciences Sweden AB (ISAB) is making waves in the pharmaceutical industry. With recent submissions to the FDA and new orders from global clients, the company is at the forefront of inhalation therapy development. Their innovative ...
10.01.2025Inhalation Sciences receives IRS order worth SEK 212,000 from global leader in generics and biosimilarsInhalation Sciences receives IRS order worth SEK 212,000 from global leader in generics and biosimilars Fri, Jan 10, 2025 08:30 CET Report this content (Stockholm, Sweden, 10 January 2025) Inhalation Sciences AB (ISAB) has received an order...
09.01.2025Inhalation Sciences submits Project Report and Summary Data to the FDA for Final ReviewInhalation Sciences submits Project Report and Summary Data to the FDA for Final Review Thu, Jan 09, 2025 08:30 CET Report this content (Stockholm, Sweden, 9 January 2025) Inhalation Sciences Sweden AB (ISAB) is proud to announce the submis...
17.12.2024Inhalation Sciences receives new orders totalling 33,900 Euro for technical service contractsInhalation Sciences receives new orders totalling 33,900 Euro for technical service contracts Tue, Dec 17, 2024 11:32 CET Report this content (Stockholm, Sweden, 17 December 2024) Inhalation Sciences AB (publ), a world-leading research and ...
20.11.2024Inhalation Sciences AB (publ) releases Q3 Report 2024Inhalation Sciences AB (publ) releases Q3 Report 2024 Wed, Nov 20, 2024 08:30 CET Report this content (Stockholm, Sweden, 20 November, 2024) Inhalation Sciences AB announces that its Q3 Report for 2024 is now available on the company's webs...
16.10.2024A Surge in Scientific Innovation: SEK 835 Million in Grants Fueling Research BreakthroughsIn a world where knowledge is power, the Knut and Alice Wallenberg Foundation is igniting the flames of scientific discovery. With a staggering SEK 835 million allocated to 30 groundbreaking research projects, the foundation is setting the ...
16.10.2024Inhalation Sciences provides latest status update on ongoing FDA BAA dissolution research projectInhalation Sciences provides latest status update on ongoing FDA BAA dissolution research project Wed, Oct 16, 2024 08:30 CET Report this content (Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest up...
10.10.2024Publication of positive performance of ISAB’s in vitro module demonstrated in collaboration with Karolinska InstitutetPublication of positive performance of ISAB’s in vitro module demonstrated in collaboration with Karolinska Institutet Thu, Oct 10, 2024 08:30 CET Report this content A new publication demonstrates how XposeALI®, Inhalation Sciences’ in vit...
28.08.2024Inhalation Sciences AB (publ) releases Q2 Report 2024Inhalation Sciences AB (publ) releases Q2 Report 2024 Wed, Aug 28, 2024 08:30 CET Report this content (Stockholm, Sweden, 28 August 2024) Inhalation Sciences AB announces that its Q2 Report for 2024 is now available on the company’s website...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In